Novel Agent Curbs Alzheimer ' s-Related Agitation Novel Agent Curbs Alzheimer ' s-Related Agitation

AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer ' s disease in the phase 3 ACCORD trial.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news